Holen Sie sich die Stockscreener-App
4.28
21.25%
0.75
Handel nachbörslich:
4.08
-0.20
-4.67%
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Top Premarket Decliners - marketscreener.com
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | O - GuruFocus
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | OGEN Stock News - GuruFocus
Oragenics (OGEN) Trading Paused Due to High Volatility | OGEN St - GuruFocus
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Oral Probiotics Supplements Gain Popularity in Digestive - openPR.com
OGEN stock touches 52-week low at $0.12 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com Australia
Oragenics announces reverse stock split to begin June 3 By Investing.com - Investing.com South Africa
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | - GuruFocus
Oragenics announces reverse stock split to begin June 3 - Investing.com Australia
Oragenics Announces Reverse Stock Split to Boost Share Price - TipRanks
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | OGEN Stock News - GuruFocus
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Worksport Secures ISO 9001 Certification at U.S. Factory, Unlocking Revenue & OEM Growth Pathways - The Manila Times
Oragenics Hosts Neurotrauma Medicine Webinar Presentation - TipRanks
Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewswire
Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus
Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia
Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria
Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq
CSW Industrials Announces Date for Fiscal Fourth Quarter and Full Year 2025 Earnings Release Conference Call - The Manila Times
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
0.09%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):